Malaria-Infected Mice Live until at Least Day 30 after a New Monomeric Trioxane Combined with Mefloquine Are Administered Together in a Single Low Oral Dose
- 8 July 2009
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 52 (23), 7458-7462
- https://doi.org/10.1021/jm9005934
Abstract
In only five simple steps and 48% overall yield from the natural trioxane artemisinin, the thermally and hydrolytically stable trioxane fluoroanilide 4b has been prepared. Upon one oral dose of only 6.8 mg/kg of monomeric trioxane 4b combined with 20 mg/kg of mefloquine hydrochloride, all of the malaria-infected mice lived until at least day 30 post infection. Of the five mice in this surviving group, four (80%) were completely cured (no parasites in their blood) and one mouse had 4% blood parasitemia. Importantly, the efficacy of this ACT chemotherapy using monomeric trioxane 4b plus mefloquine hydrochloride is considerably better than the efficacy under the same conditions using the popular trioxane drug artemether plus mefloquine hydrochloride.This publication has 15 references indexed in Scilit:
- Efficacy and safety of a fixed dose artesunate-sulphamethoxypyrazine-pyrimethamine compared to artemether-lumefantrine for the treatment of uncomplicated falciparum malaria across Africa: a randomized multi-centre trialMalaria Journal, 2009
- The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparumMalaria Journal, 2009
- Pharmacokinetics and Pharmacodynamics of Endoperoxide AntimalarialsCurrent Drug Metabolism, 2009
- Malaria-Infected Mice Are Cured by a Single Oral Dose of New Dimeric Trioxane Sulfones Which Are Also Selectively and Powerfully Cytotoxic to Cancer CellsJournal of Medicinal Chemistry, 2009
- Synthesis, Antimalarial Activity, and Intracellular Targets of MEFAS, a New Hybrid Compound Derived from Mefloquine and ArtesunateAntimicrobial Agents and Chemotherapy, 2008
- Efficacy and safety of dihydroartemisinin-piperaquineTransactions of the Royal Society of Tropical Medicine and Hygiene, 2007
- Identification of an antimalarial synthetic trioxolane drug development candidateNature, 2004
- Artesunate combinations for treatment of malaria: meta-analysisThe Lancet, 2004
- Orally Active, Antimalarial, Anticancer, Artemisinin-Derived Trioxane Dimers with High Stability and EfficacyJournal of Medicinal Chemistry, 2003
- Antitumor Activity of Novel Deoxoartemisinin Monomers, Dimers, and TrimerJournal of Medicinal Chemistry, 2003